Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia
- 作者：Wing-Yan Au ; Clarence C.K. Lam ; Chor-Sang Chim ; Annie W.K. Pang and Yok-Lam Kwong
- 关键词：Alemtuzumab ; Pure red cell aplasia
- 刊名：Leukemia Research
- 出版年：2005
- 期刊代码：186_01452126
- 类别：med
- 出版时间：2005
- 卷：29
- 期：10
- 页码：1213-1215
- 文件大小：138 K
摘要
Two patients with pure red cell aplasia (PRCA) refractory to anti-thymocyte globulin, prednisolone, cyclophosphamide, fludarabine, mitoxantrone, dexamethasone and cyclosporine, were treated with alemtuzumab (anti-CD52 antibody). Case 1, a 35-year-old man with idiopathic PRCA, remitted completely with 130 mg of alemtuzumab. Case 2, a 42-year-old man with PRCA due to T-cell large granular lymphocyte (T-LGL) leukaemia, achieved complete remission of the PRCA with 490 mg of alemtuzumab, although the T-LGL leukaemia responded only transiently. There were no significant side effects, and normalization of erythropoiesis was durable. Alemtuzumab is active in PRCA that is idiopathic or secondary to T-cell lymphoproliferative diseases.